Last reviewed · How we verify

Peri-operative chemotherapy — Competitive Intelligence Brief

Peri-operative chemotherapy (Peri-operative chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Peri-operative chemotherapy (Peri-operative chemotherapy) — The First Affiliated Hospital with Nanjing Medical University. Peri-operative chemotherapy administers cytotoxic chemotherapy drugs before and/or after surgical resection to eliminate micrometastatic disease and improve overall survival in cancer patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Peri-operative chemotherapy TARGET Peri-operative chemotherapy The First Affiliated Hospital with Nanjing Medical University phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peri-operative chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/peri-operative-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: